202 related articles for article (PubMed ID: 36525602)
21. Systemic treatments for resectable carcinoma of the esophagus.
Leowattana W; Leowattana P; Leowattana T
World J Gastroenterol; 2023 Aug; 29(30):4628-4641. PubMed ID: 37662861
[TBL] [Abstract][Full Text] [Related]
22. Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer.
Tomasello G; Ghidini M; Barni S; Passalacqua R; Petrelli F
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):649-660. PubMed ID: 28349718
[TBL] [Abstract][Full Text] [Related]
23. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.
Bystricky B; Okines AF; Cunningham D
Drugs; 2011 Mar; 71(5):541-55. PubMed ID: 21443280
[TBL] [Abstract][Full Text] [Related]
24. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Strategies for Esophageal Cancer: Role of Immunotherapy and Positron emission tomography (PET)-Guided Strategies.
Barron CC; Wang X; Elimova E
Thorac Surg Clin; 2023 May; 33(2):197-208. PubMed ID: 37045489
[TBL] [Abstract][Full Text] [Related]
27. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.
Kakeji Y; Oshikiri T; Takiguchi G; Kanaji S; Matsuda T; Nakamura T; Suzuki S
Esophagus; 2021 Jan; 18(1):25-32. PubMed ID: 32964312
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature.
Krishnamurthy A; Mohanraj N; Radhakrishnan V; John A; Selvaluxmy G
Indian J Cancer; 2017; 54(4):646-651. PubMed ID: 30082551
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma.
Lau DK; Athauda A; Chau I
Expert Opin Pharmacother; 2021 Aug; 22(11):1429-1441. PubMed ID: 33688789
[No Abstract] [Full Text] [Related]
30. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
[TBL] [Abstract][Full Text] [Related]
31. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.
Shi J; Li N; Tang Y; Jiang L; Yang L; Wang S; Song Y; Liu Y; Fang H; Lu N; Qi S; Chen B; Li Z; Liu S; Wang J; Wang W; Zhu S; Yang J; Li Y; Zhao D; Jin J
BMC Gastroenterol; 2022 Jul; 22(1):359. PubMed ID: 35902798
[TBL] [Abstract][Full Text] [Related]
32. A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer.
Dai H; Liu M; Li X; Li T; Huang W; Liao J; Li Y; Fang S
World J Surg Oncol; 2022 Aug; 20(1):267. PubMed ID: 36008813
[TBL] [Abstract][Full Text] [Related]
33. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
[TBL] [Abstract][Full Text] [Related]
34. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
37. Multimodal treatments for resectable esophagogastric junction cancer: A Bayesian network meta-analysis.
Shao P; Nima S; Tse Y; Suolang Z; Pubu C
Langenbecks Arch Surg; 2023 Mar; 408(1):123. PubMed ID: 36934163
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
39. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
